Guided Therapeutics - GTHP Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guided Therapeutics - GTHP

GTHP 0.270

0.0%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: caly	11/6/2010 2:34:06 PM
	of 118

medicaldevices-business-review.com Medical Devices Business Review Guided Therapeutics receives federal grant for LightTouch scanner Published: 05-Nov-2010 Guided Therapeutics has received a $244,479 federal grant to advance its LightTouch Cervical Scanner, currently under FDA review for market approval. The LightTouch, which consists of a base unit and single-patient-use calibration disposable, scans the cervix with light to identify cancer and pre-cancer painlessly and non-invasively. Guided Therapeutics’ patented biophotonic technology is able to distinguish between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Guided Therapeutics said that the LightTouch test does not require laboratory analysis or a tissue sample and provides results immediately and eliminate costly unnecessary testing. The US Treasury’s qualifying therapeutic discovery projects program grant is the seventh federal award, totaling more than $6m, given to support the development of the LightTouch. Guided Therapeutics president and CEO Mark Faupel said that they are pleased to receive the grant and the recognition it brings to LightTouch non-invasive cervical disease detection technology. “The LightTouch represents a breakthrough in early cancer detection, when the disease is most treatable, potentially improving cancer care outcomes in cervical cancer, while reducing the costs associated with unnecessary biopsies,” Faupel said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next